Stefan Constantinescu, MD, PhD is Professor of Molecular and Cell Biology at Université catholique de Louvain, de Duve Institute and Member of the Ludwig Institute for Cancer Research. He received his MD and PhD in Virology from the Carol Davila University of Medicine and Pharmacy in Bucharest in 1991, and has been trained as a postdoctoral fellow with Professor Harvey F. Lodish at Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology (1995-2000.)

In 2000 he started his independent laboratory at the Ludwig Institute for Cancer Research in Brussels where he studies the structure and function of cytokine receptors, Janus kinases and STATs, as well as signaling in normal and

pathological blood formation. Since 2009 he is a Member of the Ludwig Institute for Cancer Research and since 2015 a Professor of Cell and Molecular Biology at Université catholique de Louvain. He is also an Internal Consultant in Hematology at Clinique universitaires Saint Luc in Brussels. Starting April 2021 Prof. Constantinescu  spends 25% of his time as Senior Group Leader in the Nuffield Department of Medicine at Oxford University, within the Oxford Branch of the Ludwig Institute for Cancer Research working on the link between signaling in cancer and epigenetics.

His research interests revolve around structure and signaling by membrane proteins, especially cytokine receptors and their associated Janus kinases (JAKs), and also the structure and function by other transmembrane protein complexes, including growth factor receptors and amyloid precursor protein. His group contributed to the elucidation of the molecular bases myeloproliferative neoplasms (MPNs), a group of malignant clonal diseases of the hematopoietic system. His work on mutations in JAK2 and other genes in these diseases along with others led to the concept  that persistent activation of JAK2 and the receptor for thrombopoietin drives these diseases, which also contributed to the use in clinics of JAK2 inhibitors for several pathologies. He has been active in biotechnology, where recentoy he co-founded MyeloPro Diagnostics and Research in Vienna and AlsaTech, Boston MA. He is the Editor in chief of Journal of Cellular and Molecular Medicine, a Wiley & Sons open access journal. For his research he received the Five Year Prize for Basic Medical Sciences of the Federal Belgian Government in 2015 and the 2021 Alexandre and Gaston Tytgat Prize.

He has been elected to Membership at the Royal Academy of Medicine of Belgium, the Romanian Academy of Medical Sciences and the Romanian Academy (Honorary Foreign Member). In 2021 he has been elected President of the Federation of European Academies of Medicine (FEAM) for 3 years (2021-2024). He will be President of the Royal Academy of Medicine of Belgium during the year of 2022.